Mario Eisenberger

2.2k total citations
32 papers, 1.5k citations indexed

About

Mario Eisenberger is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mario Eisenberger has authored 32 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mario Eisenberger's work include Prostate Cancer Treatment and Research (26 papers), Prostate Cancer Diagnosis and Treatment (13 papers) and Radiopharmaceutical Chemistry and Applications (9 papers). Mario Eisenberger is often cited by papers focused on Prostate Cancer Treatment and Research (26 papers), Prostate Cancer Diagnosis and Treatment (13 papers) and Radiopharmaceutical Chemistry and Applications (9 papers). Mario Eisenberger collaborates with scholars based in United States, Canada and Netherlands. Mario Eisenberger's co-authors include Frederick J. Dorey, Elizabeth B. Humphreys, Leslie A. Mangold, Patrick C. Walsh, Stephen J. Freedland, Michael A. Carducci, George J. Netto, Jonathan I. Epstein, Howard I. Scher and Manuel Collado and has published in prestigious journals such as Nature, Journal of Clinical Oncology and The Journal of Urology.

In The Last Decade

Mario Eisenberger

31 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mario Eisenberger United States	14	981	398	366	247	246	32	1.5k
Abdel‐Aziz A. Elgamal United States	17	902 0.9×	242 0.6×	199 0.5×	310 1.3×	141 0.6×	24	1.4k
Vincent van der Noort Netherlands	23	1.4k 1.5×	1.3k 3.2×	332 0.9×	362 1.5×	294 1.2×	133	2.5k
Edoardo Francini Italy	20	632 0.6×	554 1.4×	215 0.6×	291 1.2×	75 0.3×	73	1.2k
Faith E. Nathan United States	23	1.2k 1.2×	1.4k 3.5×	188 0.5×	317 1.3×	291 1.2×	45	2.1k
Edgar Ben‐Josef United States	19	973 1.0×	408 1.0×	339 0.9×	176 0.7×	31 0.1×	34	1.6k
Ulrika Harmenberg Sweden	23	1.0k 1.1×	736 1.8×	281 0.8×	375 1.5×	262 1.1×	57	1.7k
B.Y. Yeap United States	20	1.0k 1.0×	805 2.0×	149 0.4×	238 1.0×	111 0.5×	65	2.0k
Bradley Curtis Carthon United States	20	706 0.7×	922 2.3×	135 0.4×	225 0.9×	321 1.3×	115	1.7k
Atsushi Horiike Japan	28	1.3k 1.3×	1.3k 3.3×	140 0.4×	391 1.6×	108 0.4×	107	2.1k
Julie S. Larsen United States	13	1.3k 1.3×	322 0.8×	494 1.3×	416 1.7×	48 0.2×	31	1.8k

Countries citing papers authored by Mario Eisenberger

Since Specialization

Citations

This map shows the geographic impact of Mario Eisenberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Eisenberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Eisenberger more than expected).

Fields of papers citing papers by Mario Eisenberger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Eisenberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Eisenberger. The network helps show where Mario Eisenberger may publish in the future.

Co-authorship network of co-authors of Mario Eisenberger

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Eisenberger. A scholar is included among the top collaborators of Mario Eisenberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Eisenberger. Mario Eisenberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gravis, Gwénaëlle, Jean‐Marie Boher, Yu‐Hui Chen, et al.. (2018). Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. European Urology. 73(6). 847–855. 157 indexed citations

Rowe, Steven P., Katarzyna J. Macura, Esther Mena, et al.. (2016). PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Molecular Imaging and Biology. 18(3). 411–419. 199 indexed citations

Mitri, Diletta Di, Alberto Toso, Jingjing Chen, et al.. (2014). Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature. 515(7525). 134–137. 289 indexed citations

González-Roibón, Nilda, Jaeyeon Kim, Sheila F. Faraj, et al.. (2014). Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy. Urology. 83(6). 1444.e1–1444.e6. 24 indexed citations

Netto, George J., Mario Eisenberger, & Jonathan I. Epstein. (2010). Interobserver Variability in Histologic Evaluation of Radical Prostatectomy Between Central and Local Pathologists: Findings of TAX 3501 Multinational Clinical Trial. Urology. 77(5). 1155–1160. 54 indexed citations

Wang, Wenle, Fabio Tavora, Rajni Sharma, Mario Eisenberger, & George J. Netto. (2008). PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma. Urologic Oncology Seminars and Original Investigations. 27(5). 525–528. 45 indexed citations

Kibel, Adam S., Mario Eisenberger, Joel Picus, et al.. (2008). GENE EXPRESSION PROFILING FOR THE PREDICTION OF THERAPEUTIC RESPONSE TO ADJUVANT DOCETAXEL FOR HIGH RISK LOCALIZED PROSTATE CARCINOMA. The Journal of Urology. 179(4S). 47–47. 2 indexed citations

Carducci, Michael A., Michael J. Morris, Mario Eisenberger, et al.. (2007). Phase I dose-escalation study of AGS-PSCA, an anti-PSCA human antibody, in castration-resistant prostate cancer. Molecular Cancer Therapeutics. 6. 2 indexed citations

Rathkopf, Dana E., Michael A. Carducci, Susan F. Slovin, et al.. (2007). A phase II trial of rapid androgen cycling and docetaxel (Doc) in prostate cancer patients with a rising prostate-specific antigen (PSA) in the noncastrate state. Journal of Clinical Oncology. 25(18_suppl). 5004–5004. 2 indexed citations

10.

Kattan, Michael W., Joel Picus, Robert Dreicer, et al.. (2006). 1589: Adjuvant Weekly Docetaxel for High-Risk Prostate Cancer Patients After Radical Prostatectomy. The Journal of Urology. 175(4S). 512–512.

11.

Makarov, Danil V., Elizabeth B. Humphreys, Leslie A. Mangold, et al.. (2006). 1191: Survival Following Hormonal Therapy: Men who Develop Metastasis More than Five Years Following Radical Prostatectomy Live Longer. The Journal of Urology. 175(4S). 383–384. 1 indexed citations

12.

Slovin, Susan F., Michael A. Carducci, Роберто Пили, et al.. (2005). The men’s cycle plus docetaxel (Doc) in prostate cancer patients with rising PSAs in the non-castrate state. Journal of Clinical Oncology. 23(16_suppl). 4564–4564. 2 indexed citations

13.

Rosenbaum, Eli, Adam S. Kibel, Bruce J. Roth, et al.. (2005). A pilot multicenter phase II study of adjuvant docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data. Journal of Clinical Oncology. 23(16_suppl). 4565–4565. 5 indexed citations

14.

Galsky, Matthew D., Mario Eisenberger, William K. Kelly, et al.. (2004). Phase I trial of MLN2704 in patients with castrate-metastatic prostate cancer (CMPC). Journal of Clinical Oncology. 22(14_suppl). 4592–4592. 2 indexed citations

15.

Galsky, Matthew D., Mario Eisenberger, William Kevin Kelly, et al.. (2004). Phase I trial of MLN2704 in patients with castrate-metastatic prostate cancer (CMPC). Journal of Clinical Oncology. 22(14_suppl). 4592–4592. 5 indexed citations

16.

Sokoll, Lori J., et al.. (2002). Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. Urology. 60(4). 24–30. 24 indexed citations

17.

Marshall, M. Ernest, Brent A. Blumenstein, E. David Crawford, et al.. (1994). Phase II Trial of Amonafide for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate. American Journal of Clinical Oncology. 17(6). 514–515. 16 indexed citations

18.

Eisenberger, Mario, Christine Engstrom, Jeffrey S. Abrams, et al.. (1992). Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs. 10(2). 89–91. 4 indexed citations

19.

Nanus, David M., et al.. (1988). Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. Investigational New Drugs. 6(3). 239–241. 7 indexed citations

20.

Crawford, E. David, et al.. (1987). A comparison of leuprolide with flutamide and leuprolide in previously untreated patients with clinical stage D2. European Journal of Cancer and Clinical Oncology. 23(8). 1235–1235. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact